US4401647A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiolabeled neoglycopeptides
Assignee: University of California Berkeley
•
Filing: 1980-03-03
•
Granted: 1983-08-30
•
Expires: 2000-03-03
Abstract
Abstract Radiopharmaceuticals and method are provided for scintigraphic evaluation of the liver. The radiopharmaceuticals comprise a radionuclide (technetium) labeled neoglycoprotein which provides for specific binding of the radiopharmaceutical to hepatocytes and allows for accurate determination of rates of binding and release of Tc-99m to and from the liver. The observed rates may then be used to determine diseased states, conveniently using an appropriate algorithm for the calculation.
Inventors
- 👤 Kenneth A. Krohn
- 👤 David R. Vera
- 👤 Robert C. Stadalnik
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 13:11
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/081; A61K2123/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
80 words
In a method for clinical scintigraphic hepatic imaging in a host, the improvement which comprises using as the imaging composition a composition comprised of a synthetic neoglycoprotein-Tc-99m conjugate of at least about 20,000 molecular weight and having at least one galactosyl or glucosyl residue per 20,000 molecular weight, said protein being nonimmunogenic to said host and exhibiting negligible biochemical affinity for receptor sites or physiological compartments other than the liver, wherein the amount of Tc-99m is at last 0.10 mCi/mg.
Claim 2
Dependent Claim
80 words
In a method for clinical scintigraphic hepatic imaging in a host, the improvement which comprises using as the imaging composition a composition comprised of a synthetic neoglycoprotein-Tc-99m conjugate of at least about 20,000 molecular weight and having at least one galactosyl or glucosyl residue per 20,000 molecular weight, said protein being nonimmunogenic to said host and exhibiting negligible biochemical affinity for receptor sites or physiological compartments other than the liver, wherein the amount of Tc-99m is at last 0.10 mCi/mg.
Claim 3
Dependent Claim
13 words
A method according to claim 1, wherein said glycoprotein is galactosyl serum albumin.
Claim 4
Dependent Claim
36 words
A method according to claim 1 or 2, which includes the steps of determining the rate of increase in the amount of Tc-99m in the liver and the rate of release of Tc-99m from the liver.
Claim 5
Dependent Claim
22 words
A method according to claim 1, wherein said glycoprotein is a galactosyl serum albumin, having from about 5 to 40 galactosyl groups.
Claim 6
Dependent Claim
43 words
A composition of matter comprising a galactosyl or glucosyl substituted serum albumin, having from about 5 to 40 galactosyl or glucosyl groups, combined with a reductant for pertechnetate sufficient to provide Tc-99m in an amount of from about 1 to 100 mCi/mg albumin.
Claim 7
Dependent Claim
43 words
A composition of matter comprising a galactosyl or glucosyl substituted serum albumin, having from about 5 to 40 galactosyl or glucosyl groups, combined with a reductant for pertechnetate sufficient to provide Tc-99m in an amount of from about 1 to 100 mCi/mg albumin.
Claim 8
Dependent Claim
21 words
A composition of matter according to claim 5, wherein said reductant is a stannous salt and said composition is galactosyl substituted.
Claim 9
Independent Claim
123 words
A method for diagnosing liver disease states which comprises: introducing into a host a predetermined amount of a radionuclide-containing radiopharmaceutical specifically binding to hepatocytes of the liver, said radiopharmaceutical comprising a neoglycoprotein-Tc-99m conjugate of at least about 20,000 molecular weight and having at least about one galactosyl or glucosyl residue per 20,000 molecular weight; monitoring the radioactive emissions from at least one of the regions: liver, urinary bladder, precordium, or carotid artery, and determining data concerning at least two of (1) the rate of uptake of the radionuclide by said region; (2) the emissions from at least one site of said region; and (3) the release of the radionuclide from said region; and analyzing the data as diagnostic of a liver disease state.
Claim 10
Independent Claim
123 words
A method for diagnosing liver disease states which comprises: introducing into a host a predetermined amount of a radionuclide-containing radiopharmaceutical specifically binding to hepatocytes of the liver, said radiopharmaceutical comprising a neoglycoprotein-Tc-99m conjugate of at least about 20,000 molecular weight and having at least about one galactosyl or glucosyl residue per 20,000 molecular weight; monitoring the radioactive emissions from at least one of the regions: liver, urinary bladder, precordium, or carotid artery, and determining data concerning at least two of (1) the rate of uptake of the radionuclide by said region; (2) the emissions from at least one site of said region; and (3) the release of the radionuclide from said region; and analyzing the data as diagnostic of a liver disease state.
Claim 11
Dependent Claim
12 words
A method according to claim 7, wherein said radiopharmaceutical is Tc-99m-gal neoglycoalbumin.
Claim 12
Independent Claim
20 words
A method according to any of claims 7 or 8, wherein at least one of said regions is said liver.
References Cited (Backward Citations)
US4010251A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-29 | 1987-02-28 | 1987-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-29 | 1991-02-28 | 1991-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-29 | 1995-02-28 | 1995-08-30 | $7700.00 | Window Closed / Lapsed |